Peripheral T Cell Lymphoma
Conditions
Interventions
1: Chidamide with Prednisone, Cyclophosphamide, Etoposide, and Methotrexate
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathologically diagnosed peripheral T cell lymphoma (PTCL), exclude NK/T cell lymphoma; 2. Patients with non-remission or relapse following remission after at least one session of systemic treatment (including chemotherapy, stem cell transplantation, ect); 3. Patients unavailable for hemapoietic stem cell transplantation for various reasons; 4. Aged 18 to 75 years old, male or female; 5. ECOG value 0-1; 6. The absolute value of neutriphils >=1.5×10^9/L, platelet >=90×10^9/L, Hb >=90g/L; 7. Expected survival >=3 months; 8. Did not have radiotherapy, chemotherapy, targeted therapy, or hemapoietic stem cell transplantation within the past 4 weeks prior to inclusion; 9. Willing to sign the written consent.
Exclusion criteria
Exclusion criteria: Patients with any of the folling should be excluded: 1. Women during pregnancy, lactation or fertile women who are not willing to take contraceptive measures; 2. Patients with >=10mm end-diastolic pericardial dark zone on cardiac ultrasonography; 3. Patients with transplanted organ/organs; 4. Patients that have received symptomatic treatment for bone-marrow toxicity within 7 days prior to inclusion; 5. Patients with active hemorrhage; 6. Patients with impaired liver function (Total bilirubin >=1.5 times of the normal maximum, ALT/AST >=2.5 times of the normal maximum. or ALT/AST>=5 times of the normal maximum for patients with infiltrative liver disease), impaired renal function (serum creatinin >=1.5 times of the normal maximum), abnormal electrolyte metabolism; 7. Patients with mental disorders or those who could not agree to consent; 8. Patients with drug use or long-time alcoholism that would impact the result of the trial; 9. Patients that the researchers find not suitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| duration of remission;progression free survival;overall survival; | — |
Countries
China
Contacts
Public ContactZhiming Li
Sun Yat-sen University Cancer Center
Outcome results
None listed